In silico drug design strategies for discovering novel tuberculosis therapeutics

References

• Primo LMDG, Roque-Borda CA, Carnero Canales CS, et al. Antimicrobial peptides grafted onto the surface of N-acetylcysteine-chitosan nanoparticles can revitalize drugs against clinical isolates of mycobacterium tuberculosis. 2024Jan 1;323:121449.
   Google Scholar
• Amaral TC, Glanzmann N, da Silva AD, et al. Synthesis, spectroscopic and structural characterizations and in vitro antimycobacterial activity of silver(I) complexes with sulfapyridine (SPY) and sulfamerazine (SM). J Mol Struct. 2024;1300:137234. doi: 10.1016/j.molstruc.2023.137234
   Web of Science ®Google Scholar
• World Health Organization. Global Tuberculosis Report. 2022.
   Google Scholar
• Healy C, Gouzy A, Ehrt S, et al. Peptidoglycan Hydrolases RipA and Ami1 are critical for replication and persistence of mycobacterium tuberculosis in the host. MBio. 2020;11(2):11. doi: 10.1128/mBio.03315-19
   Web of Science ®Google Scholar
• World Health Organization. Global tuberculosis report 2023 [Internet]. Geneva. 2023; [cited 2023 Nov 6]. Available from: https://www.who.int/publications/i/item/9789240083851
   Google Scholar
• Shaker B, Ahmad S, Lee J, et al. In silico methods and tools for drug discovery. Comput Biol Med. 2021;137:104851. doi: 10.1016/j.compbiomed.2021.104851
   PubMed Web of Science ®Google Scholar
• Yu D, Wang L, Wang Y. Recent advances in application of computer-aided drug design in anti-influenza a virus drug discovery. Int J Mol Sci. 2022;23(9):4738. doi: 10.3390/ijms23094738
   PubMed Web of Science ®Google Scholar
• Sona R, Kanmani S, Kumar SS, et al. Drug repositioning using computer-aided drug design (CADD). Curr Pharm Biotechnol. 2023:24. doi:10.2174/1389201024666230821103601
   Google Scholar
• Bassani D, Moro S. Past, present, and future perspectives on computer-aided drug design methodologies. Molecules. 2023;28:3906. doi: 10.3390/molecules28093906
   PubMed Web of Science ®Google Scholar
• Geronikaki A, Dubey G, Petrou A, et al. Computer-aided drug design: an overview. In: Cheminf QSAR Mach Learn Appl Novel Drug Dev. Elsevier; 2023. p. 39–68. https://www.sciencedirect.com/science/article/abs/pii/B9780443186387000244
   Google Scholar
• Wätzig H, Oltmann-Norden I, Steinicke F, et al. Data quality in drug discovery: the role of analytical performance in ligand binding assays. J Comput Aided Mol Des. 2015;29(9):847–865. doi: 10.1007/s10822-015-9851-6
   PubMed Web of Science ®Google Scholar
• Turzo SBA, Hantz ER, Lindert S. Applications of machine learning in computer-aided drug discovery. QRB Discov. 2022;3:e14.
   PubMedGoogle Scholar
• Bruch EM, Petrella S, Bellinzoni M. Structure-based drug design for tuberculosis: challenges still ahead. Appl Sci. 2020;10(12):4248. doi: 10.3390/app10124248
   Google Scholar
• Gautam V, Gaurav A, Masand N, et al. Artificial intelligence and machine-learning approaches in structure and ligand-based discovery of drugs affecting central nervous system. Mol Divers. 2023;27(2):959–985. doi: 10.1007/s11030-022-10489-3
   PubMed Web of Science ®Google Scholar
• Reid M, Agbassi YJP, Arinaminpathy N, et al. Scientific advances and the end of tuberculosis: a report from the lancet commission on tuberculosis. Lancet. 2023;402(10411):1473–1498. doi: 10.1016/S0140-6736(23)01379-X
   PubMed Web of Science ®Google Scholar
• Dartois VA, Rubin EJ. Anti-tuberculosis treatment strategies and drug development: challenges and priorities. Nat Rev Microbiol. 2022;20(11):685–701. doi: 10.1038/s41579-022-00731-y
   PubMed Web of Science ®Google Scholar
• Silva APB, Roque-Borda CA, Carnero Canales CS, et al. Activity of bacteriophage d29 loaded on nanoliposomes against macrophages infected with mycobacterium tuberculosis. Diseases. 2023;11(4):150. doi: 10.3390/diseases11040150
   PubMedGoogle Scholar
• Alsayed SSR, Gunosewoyo H. Tuberculosis: pathogenesis, current treatment regimens and new drug targets. Int J Mol Sci. 2023;24(6):5202. doi: 10.3390/ijms24065202
   PubMed Web of Science ®Google Scholar
• Hetta HF, Ahmed EA, Hemdan AG, et al. Modulation of rifampicin-induced hepatotoxicity using poly(lactic-co-glycolic acid) nanoparticles: a study on rat and cell culture models. Nanomedicine. 2020;15(14):1375–1390. doi: 10.2217/nnm-2020-0001
   PubMed Web of Science ®Google Scholar
• Fox GJ, Dobler CC, Marais BJ, et al. Preventive therapy for latent tuberculosis infection – the promise and the challenges. Inter J Infect Dis. 2017;56:68–76. doi: 10.1016/j.ijid.2016.11.006
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yew W-W. Mechanisms of drug resistance in mycobacterium tuberculosis: update 2015. Int J Tuberc Lung Dis. 2015;19(11):1276–1289. doi: 10.5588/ijtld.15.0389
   PubMed Web of Science ®Google Scholar
• Lei S, Gu R, Ma X. Clinical perspectives of isoniazid-induced liver injury. Liver Res. 2021;5(2):45–52. doi: 10.1016/j.livres.2021.02.001
   Google Scholar
• Takayama K, Kilburn JO. Inhibition of synthesis of arabinogalactan by ethambutol in mycobacterium smegmatis. Antimicrob Agents Chemother. 1989;33(9):1493–1499. doi: 10.1128/AAC.33.9.1493
   PubMed Web of Science ®Google Scholar
• Reingewertz TH, Meyer T, McIntosh F, et al. Differential sensitivity of mycobacteria to isoniazid is related to differences in KatG-mediated enzymatic activation of the drug. Antimicrob Agents Chemother. 2020;64(2):64. doi: 10.1128/AAC.01899-19
   Web of Science ®Google Scholar
• Muhammad N, Mehboob S, Abbas M. Pyrazinamide induced hyperuricemia in the induction phase of anti-tuberculosis therapy. Pak J Med Health Sci. 2021;15(5):1136–1138. doi: 10.53350/pjmhs211551136
   Web of Science ®Google Scholar
• Hussain Z, Zhu J, Ma X. Metabolism and Hepatotoxicity of Pyrazinamide, an Antituberculosis Drug. Drug Metab Dispos. 2021;49(8):679–682. doi: 10.1124/dmd.121.000389
   PubMed Web of Science ®Google Scholar
• Njire M, Tan Y, Mugweru J, et al. Pyrazinamide resistance in Mycobacterium tuberculosis: review and update. Adv Med Sci. 2016;61(1):63–71. doi: 10.1016/j.advms.2015.09.007
   PubMed Web of Science ®Google Scholar
• Pang Y, Zhu D, Zheng H, et al. Prevalence and molecular characterization of pyrazinamide resistance among multidrug-resistant mycobacterium tuberculosis isolates from Southern China. BMC Infect Dis. 2017;17(1):711. doi: 10.1186/s12879-017-2761-6
   PubMed Web of Science ®Google Scholar
• Bandyopadhyay S, Banerjee S, Bandyopadhyay S, et al. A prospective evaluation of ocular toxicity in patients receiving ethambutol as anti-tubercular therapy. Sudanese J Ophthalmol. 2020;12(1):12. doi: 10.4103/sjopthal.sjopthal_4_20
   Google Scholar
• Sun Q, Xiao T, Liu H, et al. Mutations within embCAB are associated with variable level of ethambutol resistance in mycobacterium tuberculosis isolates from China. Antimicrob Agents Chemother. 2018;62(1):62. doi: 10.1128/AAC.01279-17
   Web of Science ®Google Scholar
• Cohen K, Maartens G. A safety evaluation of bedaquiline for the treatment of multi-drug resistant tuberculosis. Expert Opin Drug Saf. 2019;18(10):875–882. doi: 10.1080/14740338.2019.1648429
   PubMed Web of Science ®Google Scholar
• Worley MV, SJ E. Bedaquiline: A Novel Antitubercular Agent for the Treatment of Multidrug-Resistant Tuberculosis. Pharmacother J Human Pharmacol Drug Ther. 2014;34(11):1187–1197. doi: 10.1002/phar.1482
   Google Scholar
• Nguyen TVA, Anthony RM, Bañuls A-L, et al. Bedaquiline resistance: its emergence, mechanism, and prevention. Clinl Infect Dis. 2018;66(10):1625–1630. doi: 10.1093/cid/cix992
   PubMed Web of Science ®Google Scholar
• Kato H, Hagihara M, Asai N, et al. A systematic review and meta-analysis of myelosuppression in pediatric patients treated with linezolid for gram-positive bacterial infections. J Infect Chemother. 2021;27(8):1143–1150. doi: 10.1016/j.jiac.2021.03.003
   PubMed Web of Science ®Google Scholar
• Oehadian A, Santoso P, Menzies D, et al. Concise clinical review of hematologic toxicity of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis: role of mitochondria. Tuberc Respir Dis (Seoul). 2022;85(2):111–121. doi: 10.4046/trd.2021.0122
   PubMed Web of Science ®Google Scholar
• Srivastava S, Magombedze G, Koeuth T, et al. Linezolid Dose That Maximizes Sterilizing Effect While Minimizing Toxicity and Resistance Emergence for Tuberculosis. Antimicrob Agents Chemother. 2017;61(8):61. doi: 10.1128/AAC.00751-17
   Web of Science ®Google Scholar
• Tanneau L, Karlsson MO, Rosenkranz SL, et al. Assessing prolongation of the corrected QT interval with Bedaquiline and delamanid coadministration to predict the cardiac safety of simplified dosing regimens. Clin Pharmacol Ther. 2022;112(4):873–881. doi: 10.1002/cpt.2685
   PubMed Web of Science ®Google Scholar
• Blair HA, LJ S. Delamanid: a review of its use in patients with multidrug-resistant tuberculosis. Drugs. 2015;75(1):91–100. doi: 10.1007/s40265-014-0331-4
   PubMed Web of Science ®Google Scholar
• Nguyen TVA, Anthony RM, Cao TTH, et al. Delamanid resistance: update and clinical management. Clinl Infect Dis. 2020;71(12):3252–3259. doi: 10.1093/cid/ciaa755
   PubMed Web of Science ®Google Scholar
• Goff A, Cantillon D, Muraro Wildner L, et al. Multi-Omics technologies applied to tuberculosis drug discovery. Appl Sci. 2020;10(13):4629. doi: 10.3390/app10134629
   Google Scholar
• Tiwari D, Martineau AR. Inflammation-mediated tissue damage in pulmonary tuberculosis and host-directed therapeutic strategies. Semin Immunol. 2023;65:101672. doi: 10.1016/j.smim.2022.101672
   PubMedGoogle Scholar
• Raslan MA, Raslan SA, Shehata EM, et al. Advances in the applications of bioinformatics and Chemoinformatics. Pharmaceuticals. 2023;16(7):1050. doi: 10.3390/ph16071050
   Web of Science ®Google Scholar
• Perveen S, Sharma R. Screening approaches and therapeutic targets: the two driving wheels of tuberculosis drug discovery. Biochem Pharmacol. 2022;197:114906. doi: 10.1016/j.bcp.2021.114906
   PubMed Web of Science ®Google Scholar
• Italia A, Shaik MM, Peri F. Emerging Extracellular Molecular Targets for Innovative Pharmacological Approaches to Resistant Mtb Infection. Biomolecules. 2023;13(6):999. doi: 10.3390/biom13060999
   PubMed Web of Science ®Google Scholar
• Ejalonibu MA, Ogundare SA, Elrashedy AA, et al. Drug discovery for Mycobacterium tuberculosis using structure-based computer-aided drug design approach. Int J Mol Sci. 2021;22(24):13259. doi: 10.3390/ijms222413259
   PubMed Web of Science ®Google Scholar
• Mahajan G, Mande SC. Using structural knowledge in the protein data bank to inform the search for potential host-microbe protein interactions in sequence space: application to mycobacterium tuberculosis. BMC Bioinf. 2017;18(1):201. doi: 10.1186/s12859-017-1550-y
   PubMedGoogle Scholar
• Velankar S, Burley SK, Kurisu G, et al. The Protein Data Bank Archive. Methods Mol Biol. 2021;2305:3–21.
   PubMedGoogle Scholar
• Goodsell DS, Zardecki C, Di Costanzo L, et al. RCSB protein data bank: enabling biomedical research and drug discovery. Protein Sci. 2020;29(1):52–65. doi: 10.1002/pro.3730
   PubMed Web of Science ®Google Scholar
• Sunita, Singhvi N, Singh Y, et al. Computational approaches in epitope design using DNA binding proteins as vaccine candidate in Mycobacterium tuberculosis. Infect Genet Evol. 2020;83:104357. doi: 10.1016/j.meegid.2020.104357
   PubMed Web of Science ®Google Scholar
• Duvaud S, Gabella C, Lisacek F, et al. Expasy, the swiss bioinformatics resource portal, as designed by its users. Nucleic Acids Res. 2021;49(W1):W216–W227. doi: 10.1093/nar/gkab225
   PubMed Web of Science ®Google Scholar
• Kingdon ADH, Alderwick LJ. Structure-based in silico approaches for drug discovery against Mycobacterium tuberculosis. Comput Struct Biotechnol J. 2021;19:3708–3719. doi: 10.1016/j.csbj.2021.06.034
   PubMed Web of Science ®Google Scholar
• Gironda-Martínez A, Donckele EJ, Samain F, et al. DNA-Encoded chemical libraries: a comprehensive review with succesful stories and future challenges. ACS Pharmacol Transl Sci. 2021;4(4):1265–1279. doi: 10.1021/acsptsci.1c00118
   PubMedGoogle Scholar
• Ruddigkeit L, Awale M, Reymond J-L. Expanding the fragrance chemical space for virtual screening. J Cheminform. 2014;6(1):27. doi: 10.1186/1758-2946-6-27
   PubMedGoogle Scholar
• Galagan JE, Sisk P, Stolte C, et al. TB database 2010: overview and update. Tuberculosis. 2010;90(4):225–235. doi: 10.1016/j.tube.2010.03.010
   PubMed Web of Science ®Google Scholar
• Rosenthal A, Gabrielian A, Engle E, et al. The TB portals: an open-access, web-based platform for global drug-resistant-tuberculosis data sharing and analysis. J Clin Microbiol. 2017;55(11):3267–3282. doi: 10.1128/JCM.01013-17
   PubMed Web of Science ®Google Scholar
• Starks AM, Avilés E, Cirillo DM, et al. Collaborative effort for a centralized worldwide tuberculosis relational sequencing data platform: figure 1. Clinl Infect Dis. 2015;61(suppl 3):S141–S146. doi: 10.1093/cid/civ610
   Web of Science ®Google Scholar
• Ekins S, Clark AM, Sarker M. TB Mobile: a mobile app for anti-tuberculosis molecules with known targets. J Cheminform. 2013;5(1):13. doi: 10.1186/1758-2946-5-13
   PubMedGoogle Scholar
• Kapopoulou A, Lew JM, Cole ST. The MycoBrowser portal: a comprehensive and manually annotated resource for mycobacterial genomes. Tuberculosis. 2011;91(1):8–13. doi: 10.1016/j.tube.2010.09.006
   PubMed Web of Science ®Google Scholar
• Usmani SS, Kumar R, Kumar V, et al. AntiTbPdb: a knowledgebase of anti-tubercular peptides. Database. 2018;2018. doi: 10.1093/database/bay025
   PubMedGoogle Scholar
• Velayati AA, Farnia P, Hoffner S. Drug-resistant mycobacterium tuberculosis: epidemiology and role of morphological alterations. J Glob Antimicrob Resist. 2018;12:192–196. doi: 10.1016/j.jgar.2017.10.006
   PubMed Web of Science ®Google Scholar
• Shleider Carnero CC, Marquez CJ, Furtado TA, et al. Advances in diagnostics and drug discovery against resistant and latent tuberculosis infection. Pharmaceutics. 2023;15(10):2409. doi: 10.3390/pharmaceutics15102409
   PubMed Web of Science ®Google Scholar
• Eka Pitaloka D A, Izzati A, Rafa Amirah S, et al. Bioinformatics analysis to uncover the potential drug targets responsible for mycobacterium tuberculosis peptidoglycan and lysine biosynthesis. Bioinform Biol Insights. 2023;17:117793222311717. doi: 10.1177/11779322231171774
   Web of Science ®Google Scholar
• Sreelatha S, Nagarajan U, Natarajan S. Protein targets in Mycobacterium tuberculosis and their inhibitors for therapeutic implications: a narrative review. Int j biol macromol. 2023;243:125022.
   PubMed Web of Science ®Google Scholar
• Mittal P, Sinha R, Kumar A, et al. Focusing on DNA repair and damage tolerance mechanisms in mycobacterium tuberculosis: an emerging therapeutic theme. Curr Top Med Chem. 2020;20(5):390–408. doi: 10.2174/1568026620666200110114322
   PubMed Web of Science ®Google Scholar
• Chandra P, Grigsby SJ, Philips JA. Immune evasion and provocation by Mycobacterium tuberculosis. Nat Rev Microbiol. 2022;20(12):750–766. doi: 10.1038/s41579-022-00763-4
   PubMed Web of Science ®Google Scholar
• Umare MD, Khedekar PB, Chikhale RV. Mycobacterial membrane protein large 3 (MmpL3) Inhibitors: a promising approach to combat tuberculosis. ChemMedchem. 2021;16(20):3136–3148. doi: 10.1002/cmdc.202100359
   PubMed Web of Science ®Google Scholar
• Sammartino JC, Morici M, Stelitano G, et al. Functional investigation of the antitubercular drug target decaprenylphosphoryl-β-D-ribofuranose-2-epimerase DprE1/DprE2 complex. Biochem Biophys Res Commun. 2022;607:49–53. doi: 10.1016/j.bbrc.2022.03.091
   PubMed Web of Science ®Google Scholar
• Bon C, Cabantous S, Julien S, et al. Solution structure of the type I polyketide synthase Pks13 from mycobacterium tuberculosis. BMC Biol. 2022;20(1):147. doi: 10.1186/s12915-022-01337-9
   PubMed Web of Science ®Google Scholar
• Prasad MS, Bhole RP, Khedekar PB, et al. Mycobacterium enoyl acyl carrier protein reductase (InhA): a key target for antitubercular drug discovery. Bioorg Chem. 2021;115:105242. doi: 10.1016/j.bioorg.2021.105242
   PubMed Web of Science ®Google Scholar
• Kermani AA, Roy R, Gopalasingam C, et al. Crystal structure of the TreS: Pep2 complex, initiating α-glucan synthesis in the GlgE pathway of mycobacteria. J Biol Chem. 2019;294(18):7348–7359. doi: 10.1074/jbc.RA118.004297
   PubMed Web of Science ®Google Scholar
• Fahrig-Kamarauskait≑ J, Würth-Roderer K, Thorbjørnsrud HV, et al. Evolving the naturally compromised chorismate mutase from Mycobacterium tuberculosis to top performance. J Biol Chem. 2020;295:17514–17534. doi: 10.1074/jbc.RA120.014924
   PubMed Web of Science ®Google Scholar
• Schumann NC, Lee KJ, Thompson AP, et al. Inhibition of mycobacterium tuberculosis dethiobiotin synthase (mt DTBS): toward next-generation antituberculosis agents. ACS Chem Biol. 2021;16(11):2339–2347. doi: 10.1021/acschembio.1c00491
   PubMed Web of Science ®Google Scholar
• MYu R, Balanda AO, Yatsyshyna AP, et al. Discovery of novel antituberculosis agents among 3-phenyl-5-(1-phenyl-1H-[1,2,3]triazol-4-yl)-[1,2,4]oxadiazole derivatives targeting aminoacyl-tRNA synthetases. Sci Rep. 2021;11(1):7162. doi: 10.1038/s41598-021-86562-y
   PubMed Web of Science ®Google Scholar
• Ahn W-C, Aroli S, Kim J-H, et al. Covalent binding of uracil DNA glycosylase UdgX to abasic DNA upon uracil excision. Nat Chem Biol. 2019;15(6):607–614. doi: 10.1038/s41589-019-0289-3
   PubMed Web of Science ®Google Scholar
• de Wet TJ, Warner DF, Mizrahi V, et al. Harnessing biological insight to accelerate tuberculosis drug discovery. Acc Chem Res. 2019;52(8):2340–2348. doi: 10.1021/acs.accounts.9b00275
   PubMed Web of Science ®Google Scholar
• Tomasi FG, Schweber JTP, Kimura S, et al. Peptidyl tRNA hydrolase is required for robust prolyl-tRNA turnover in mycobacterium tuberculosis. MBio. 2023;14(1):14. doi: 10.1128/mbio.03469-22
   Web of Science ®Google Scholar
• Alsulaimany FA, Almukadi H, Zabermawi NMO, et al. Identification of novel mycobacterium tuberculosis leucyl-tRNA synthetase inhibitor using a knowledge-based computational screening approach. J King Saud Univ Sci. 2022;34(4):102032. doi: 10.1016/j.jksus.2022.102032
   Web of Science ®Google Scholar
• Singh N, Chauhan A, Kumar R, et al. Biochemical and functional characterization of Mycobacterium tuberculosis ketol-acid reductoisomerase. Microbiology (NY). 2021;167(9):167. doi: 10.1099/mic.0.001087
   Google Scholar
• Gupta P, Thomas SE, Zaidan SA, et al. A fragment-based approach to assess the ligandability of ArgB, ArgC, ArgD and ArgF in the L-arginine biosynthetic pathway of mycobacterium tuberculosis. Comput Struct Biotechnol J. 2021;19:3491–3506. doi: 10.1016/j.csbj.2021.06.006
   PubMed Web of Science ®Google Scholar
• Jian Y, Merceron R, De Munck S, et al. Endeavors towards transformation of M. tuberculosis thymidylate kinase (MtbTMPK) inhibitors into potential antimycobacterial agents. Eur J Med Chem. 2020;206:112659. doi: 10.1016/j.ejmech.2020.112659
   PubMed Web of Science ®Google Scholar
• Antil M, Gupta V. Lessons learnt and the way forward for drug development against isocitrate lyase from mycobacterium tuberculosis. Protein Pept Lett. 2022;29(12):1031–1041. doi: 10.2174/0929866529666221006121831
   PubMed Web of Science ®Google Scholar
• de M CA, Roth CD, Ducati RG, et al. 8-mercaptoguanine-based inhibitors of mycobacterium tuberculosis dihydroneopterin aldolase: synthesis, in vitro inhibition and docking studies. J Enzym Inhib Med Chem. 2021;36(1):847–855. doi: 10.1080/14756366.2021.1900157
   PubMed Web of Science ®Google Scholar
• Ruddraraju KV, Aggarwal D, Zhang Z-Y. Therapeutic targeting of protein tyrosine phosphatases from mycobacterium tuberculosis. Microorganisms. 2020;9(1):14. doi: 10.3390/microorganisms9010014
   PubMed Web of Science ®Google Scholar
• Thapa J, Chizimu JY, Kitamura S, et al. Characterization of DNA gyrase activity and elucidation of the impact of amino acid substitution in GyrA on fluoroquinolone resistance in mycobacterium avium. Microbiol Spectr. 2023;11(3):11. doi: 10.1128/spectrum.05088-22
   Web of Science ®Google Scholar
• Thongdee P, Hanwarinroj C, Pakamwong B, et al. Virtual screening identifies novel and potent inhibitors of mycobacterium tuberculosis PknB with antibacterial activity. J Chem Inf Model. 2022;62(24):6508–6518. doi: 10.1021/acs.jcim.2c00531
   PubMed Web of Science ®Google Scholar
• Shetye GS, Franzblau SG, Cho S. New tuberculosis drug targets, their inhibitors, and potential therapeutic impact. Transl Res. 2020;220:68–97.
   PubMed Web of Science ®Google Scholar
• Brogi S, Ramalho TC, Kuca K, et al. Editorial: in silico methods for drug design and discovery. Front Chem. 2020;8:8. doi: 10.3389/fchem.2020.00612
   PubMed Web of Science ®Google Scholar
• Torres PHM, Sodero ACR, Jofily P, et al. Key topics in molecular docking for drug design. Int J Mol Sci. 2019;20(18):4574. doi: 10.3390/ijms20184574
   PubMed Web of Science ®Google Scholar
• Tao X, Huang Y, Wang C, et al. Recent developments in molecular docking technology applied in food science: a review. Int J Food Sci Technol. 2020;55(1):33–45. doi: 10.1111/ijfs.14325
   Web of Science ®Google Scholar
• Crampon K, Giorkallos A, Deldossi M, et al. Machine-learning methods for ligand–protein molecular docking. Drug Discov Today. 2022;27(1):151–164. doi: 10.1016/j.drudis.2021.09.007
   PubMed Web of Science ®Google Scholar
• Jakhar R, Dangi M, Khichi A, et al. Relevance of molecular docking studies in drug designing. Curr Bioinform. 2020;15(4):270–278. doi: 10.2174/1574893615666191219094216
   Web of Science ®Google Scholar
• Zhang Y, Zhang H, Chen Y, et al. Screening and identification of a novel anti-tuberculosis compound that targets deoxyuridine 5′-triphosphate nucleotidohydrolase. Front Microbiol. 2021;12:12. doi: 10.3389/fmicb.2021.757914
   Web of Science ®Google Scholar
• Xia M-Y, Cai Y-X, Chen J-X, et al. Synthesis, antimycobacterial evaluation, and molecular docking study of 1,2,4-triazole derivatives. J Enzym Inhib Med Chem. 2023;38(1):38. doi: 10.1080/14756366.2023.2229070
   Google Scholar
• Wen Y, Lun S, Jiao Y, et al. Structure-directed identification of pyridine-2-methylamine derivatives as MmpL3 inhibitors for use as antitubercular agents. Eur J Med Chem. 2023;255:115351. doi: 10.1016/j.ejmech.2023.115351
   PubMed Web of Science ®Google Scholar
• Wang X, Yang R, Liu S, et al. IMB-XMA0038, a new inhibitor targeting aspartate-semialdehyde dehydrogenase of Mycobacterium tuberculosis. Emerg Microbes Infect. 2021;10(1):2291–2299. doi: 10.1080/22221751.2021.2006578
   PubMed Web of Science ®Google Scholar
• Wang P, Batt SM, Wang B, et al. Discovery of novel thiophene-arylamide derivatives as DprE1 inhibitors with potent antimycobacterial activities. J Med Chem. 2021;64(9):6241–6261. doi: 10.1021/acs.jmedchem.1c00263
   PubMed Web of Science ®Google Scholar
• Wang X, Zhao W, Wang B, et al. Identification of inhibitors targeting polyketide synthase 13 of mycobacterium tuberculosis as antituberculosis drug leads. Bioorg Chem. 2021;114:105110. doi: 10.1016/j.bioorg.2021.105110
   PubMed Web of Science ®Google Scholar
• Tyagi R, Srivastava M, Singh B, et al. Identification and validation of potent mycobacterial proteasome inhibitor from Enamine library. J Biomol Struct Dyn. 2022;40(19):8644–8654. doi: 10.1080/07391102.2021.1914173
   PubMed Web of Science ®Google Scholar
• Singh K, Sharma A, Upadhyay TK, et al. Structure-based in silico and in vitro analysis reveals asiatic acid as novel potential inhibitor of mycobacterium tuberculosis maltosyl transferase. Curr Comput Aided Drug Des. 2022;18(3):213–227. doi: 10.2174/1573409918666220623105908
   PubMed Web of Science ®Google Scholar
• Shukla S, Nishanth Rao R, Bhuktar H, et al. Wang resin catalysed sonochemical synthesis of pyrazolo[4,3-d]pyrimidinones and 2,3-dihydroquinazolin-4(1H)-ones: identification of chorismate mutase inhibitors having effects on mycobacterium tuberculosis cell viability. Bioorg Chem. 2023;134:106452. doi: 10.1016/j.bioorg.2023.106452
   PubMed Web of Science ®Google Scholar
• Sharma D, Sharma S, Sinha N, et al. Novel benzoic thiazolidin-4-one derivatives targeting DevR/DosR dormancy regulator of Mycobacterium tuberculosis. J Mol Struct. 2022;1254:132278. doi: 10.1016/j.molstruc.2021.132278
   Web of Science ®Google Scholar
• El Sawy MA, Elshatanofy MM, El Kilany Y, et al. Novel hybrid 1,2,4- and 1,2,3-triazoles targeting mycobacterium tuberculosis enoyl acyl carrier protein reductase (InhA): design, synthesis, and molecular docking. Int J Mol Sci. 2022;23(9):4706. doi: 10.3390/ijms23094706
   PubMed Web of Science ®Google Scholar
• Sangepu VR, Jain KK, Bhoomireddy RD, et al. One-pot sonochemical synthesis and in silico/in vitro antitubercular evaluation of 1-methyl-3-propyl-1H-pyrazole containing polynuclear fused N-heteroarenes. J Mol Struct. 2023;1278:134909. doi: 10.1016/j.molstruc.2023.134909
   Web of Science ®Google Scholar
• Gawad J, Bonde C. Synthesis, biological evaluation and molecular docking studies of 6-(4-nitrophenoxy)-1H-imidazo[4,5-b]pyridine derivatives as novel antitubercular agents: future DprE1 inhibitors. Chem Cent J. 2018;12(1):138. doi: 10.1186/s13065-018-0515-1
   PubMedGoogle Scholar
• Raj P, Selvam K, Roy K, et al. Identification of a new and diverse set of Mycobacterium tuberculosis uracil-DNA glycosylase (MtUng) inhibitors using structure-based virtual screening: Experimental validation and molecular dynamics studies. Bioorg Med Chem Lett. 2022;76:129008. doi: 10.1016/j.bmcl.2022.129008
   PubMed Web of Science ®Google Scholar
• Puranik NV, Swami S, Misar AV, et al. The first synthesis of podocarflavone a and its analogs and evaluation of their antimycobacterial potential against mycobacterium tuberculosis with the support of virtual screening. Nat Prod Res. 2022;36(15):3879–3886. doi: 10.1080/14786419.2021.1893317
   PubMed Web of Science ®Google Scholar
• Phanumartwiwath A, Kesornpun C, Sureram S, et al. Antitubercular and antibacterial activities of isoxazolines derived from natural products: isoxazolines as inhibitors of mycobacterium tuberculosis InhA. InhA J Chem Res. 2021;45(11–12):1003–1015. doi: 10.1177/17475198211047801
   Google Scholar
• Patel T, Chauhan N, Bhatt VD, et al. Design and synthesis of novel imidazolidine-2,4-dione derivatives as InhA inhibitors: Spectral characterization, computational, and biological studies. Mater Today Proc. 2022;57:217–223. doi: 10.1016/j.matpr.2022.02.364
   Google Scholar
• Pallabothula VSK, Kerda M, Juhás M, et al. Adenosine-mimicking derivatives of 3-aminopyrazine-2-carboxamide: towards inhibitors of prolyl-tRNA synthetase with antimycobacterial activity. Biomolecules. 2022;12(11):1561. doi: 10.3390/biom12111561
   PubMed Web of Science ®Google Scholar
• Liu T, Chen J, Fan C, et al. Crystal structure, DFT calculation, molecular docking, in vitro biological activity evaluation and in silico drug-likeness prediction of (E)-N-(4-bromophenyl)-4-(2-(2-hydroxybenzylidene) hydrazine-1-carbonyl) benzenesulfonamide. J Mol Struct. 2023;1284:135319. doi: 10.1016/j.molstruc.2023.135319
   Web of Science ®Google Scholar
• Lin X, Kurz JL, Patel KM, et al. Discovery of a pyrimidinedione derivative with potent inhibitory activity against mycobacterium tuberculosis ketol–acid reductoisomerase. Chem Eur J. 2021;27(9):3130–3141. doi: 10.1002/chem.202004665
   PubMed Web of Science ®Google Scholar
• Kumar A, Rajappan R, Kini SG, et al. E-Pharmacophore model-guided design of potential DprE1 inhibitors: synthesis, in vitro antitubercular assay and molecular modelling studies. Chem Papers. 2021;75(10):5571–5585. doi: 10.1007/s11696-021-01743-3
   Web of Science ®Google Scholar
• Kulabaş N, Türe A, Bozdeveci A, et al. Novel fluoroquinolones containing 2‐arylamino‐2‐oxoethyl fragment: design, synthesis, evaluation of antibacterial and antituberculosis activities and molecular modeling studies. J Heterocycl Chem. 2022;59(5):909–926. doi: 10.1002/jhet.4430
   Web of Science ®Google Scholar
• Khurana H, Srivastava M, Chaudhary D, et al. Identification of diphenyl furan derivatives via high throughput and computational studies as ArgA inhibitors of mycobacterium tuberculosis. Int j biol macromol. 2021;193:1845–1858. doi: 10.1016/j.ijbiomac.2021.11.017
   PubMed Web of Science ®Google Scholar
• Kapp E, Calitz H, Streicher EM, et al. Discovery and biological evaluation of an adamantyl-amide derivative with likely MmpL3 inhibitory activity. Tuberculosis. 2023;141:102350. doi: 10.1016/j.tube.2023.102350
   PubMed Web of Science ®Google Scholar
• James JP, Mathew JB, Ishwar BK, et al. Design and synthesis of novel pyrimidine analogs as anti-tubercular agents targeting thymidine kinase domain. J Microb Biotech Food Sci. 2021;11(2):e1744. doi: 10.15414/jmbfs.1744
   Web of Science ®Google Scholar
• Jagatap VR, Ahmad I, Sriram D, et al. Isoflavonoid and furanochromone natural products as potential DNA gyrase inhibitors: computational, spectral, and antimycobacterial studies. ACS Omega. 2023;8(18):16228–16240. doi: 10.1021/acsomega.3c00684
   PubMed Web of Science ®Google Scholar
• Duan C, Jiang Q, Jiang X, et al. Discovery of a novel inhibitor structure of mycobacterium tuberculosis Isocitrate Lyase. Molecules. 2022;27(8):2447. doi: 10.3390/molecules27082447
   PubMed Web of Science ®Google Scholar
• Dhivya LS, Sarvesh S, AS S. Inhibition of mycobacterium tuberculosis InhA (enoyl-acyl carrier protein reductase) by synthetic Chalcones: a molecular modelling analysis and in-vitro evidence. J Biomol Struct Dyn. 2023;41(12):5399–5417. doi: 10.1080/07391102.2022.2086922
   PubMed Web of Science ®Google Scholar
• Deshpande A, Dhawale S, Bari S, et al. Design, synthesis and biological investigation of some novel quinazolin-4(3H)-one tethered 1, 3, 4-thiadiazole-thiol motifs as direct enoyl acyl carrier protein reductase inhibitors. J Pharm Res Int. 2021;617–632. doi: 10.9734/jpri/2021/v33i47A33052
   Web of Science ®Google Scholar
• Chetty S, Armstrong T, Sharma Kharkwal S, et al. New InhA inhibitors based on expanded triclosan and di-triclosan analogues to develop a new treatment for tuberculosis. Pharmaceuticals. 2021;14(4):361. doi: 10.3390/ph14040361
   Web of Science ®Google Scholar
• Chen D, Liu L, Lu Y, et al. Identification of fusarielin M as a novel inhibitor of mycobacterium tuberculosis protein tyrosine phosphatase B (MptpB). Bioorg Chem. 2021;106:104495. doi: 10.1016/j.bioorg.2020.104495
   PubMed Web of Science ®Google Scholar
• Abdelaziz OA, Othman DIA, Abdel-Aziz MM, et al. Novel diaryl ether derivatives as InhA inhibitors: design, synthesis and antimycobacterial activity. Bioorg Chem. 2022;129:106125. doi: 10.1016/j.bioorg.2022.106125
   PubMed Web of Science ®Google Scholar
• Huang H, Zhang G, Zhou Y, et al. Reverse screening methods to search for the protein targets of chemopreventive compounds. Front Chem. 2018;6:6. doi: 10.3389/fchem.2018.00138
   PubMed Web of Science ®Google Scholar
• Ruiz-Moreno AJ, Domling A, Velasco-Velázquez MA. Reverse docking for the identification of molecular targets of anticancer compounds. Methods Mol Biol. 2021;2174:31–43.
   PubMedGoogle Scholar
• Padmini T, Bhikshapathi D, Suresh K, et al. Novel aminopyrazole tagged hydrazones as anti-tubercular agents: synthesis and molecular docking studies. Med Chem (Los Angeles). 2021;17(4):344–351. doi: 10.2174/1573406416666200514084747
   Web of Science ®Google Scholar
• Atıcı R K, Şd D, Gündüz MG, et al. Urea derivatives carrying a thiophenylthiazole moiety: design, synthesis, and evaluation of antitubercular and InhA inhibitory activities. Drug Dev Res. 2022;83(6):1292–1304. doi: 10.1002/ddr.21958
   PubMed Web of Science ®Google Scholar
• Reddy BRS, Babu KS, Mulakayala N, et al. Synthesis of novel 5-oxo-1,2,4-oxadiazole derivatives as antitubercular agents and their molecular docking study toward enoyl reductase (InhA) enzyme. ChemistrySelect. 2023;8(4). doi: 10.1002/slct.202204093
   PubMed Web of Science ®Google Scholar
• Sekhara Reddy B R, Reddy Gajulapalli V P, Madhu Rekha E, et al. Design, synthesis, and in vitro biological evaluation of dehydroaripiprazole derivatives as antituberculosis agents and molecular docking study. Results Chem. 2022;4:100295. doi: 10.1016/j.rechem.2022.100295
   Google Scholar
• Nandurkar Y, Bhoye MR, Maliwal D, et al. Synthesis, biological screening and in silico studies of new N-phenyl-4-(1,3-diaryl-1H-pyrazol-4-yl)thiazol-2-amine derivatives as potential antifungal and antitubercular agents. Eur J Med Chem. 2023;258:258. doi: 10.1016/j.ejmech.2023.115548
   Web of Science ®Google Scholar
• Nandikolla A, Srinivasarao S, Khetmalis YM, et al. Design, synthesis and biological evaluation of novel 1,2,3-triazole analogues of imidazo-[1,2-a]-pyridine-3-carboxamide against mycobacterium tuberculosis. Toxicol In Vitro. 2021;74:105137. doi: 10.1016/j.tiv.2021.105137
   PubMed Web of Science ®Google Scholar
• Shinoj Kumar PP, Krishnaswamy G, Desai NR, et al. Highly facile, regio- and stereoselective synthesis of spiropyrrolidine-5-aza-2-oxindole derivatives through multicomponent 1,3-dipolar cycloaddition reaction and their in-vitro and in-silico biological studies. ChemistrySelect. 2021;6(35):9407–9414. doi: 10.1002/slct.202102118
   Web of Science ®Google Scholar
• Pradeep Kumar CB, Prathibha BS, Prasad KNN, et al. Click synthesis of 1,2,3-triazole based imidazoles: Antitubercular evaluation, molecular docking and HSA binding studies. Bioorg Med Chem Lett. 2021;36:127810. doi: 10.1016/j.bmcl.2021.127810
   PubMed Web of Science ®Google Scholar
• Emam AM, Dahal A, Singh SS, et al. Quinazoline-tethered hydrazone: a versatile scaffold toward dual anti-TB and EGFR inhibition activities in NSCLC. Arch Pharm (Weinheim). 2021;354(12). doi: 10.1002/ardp.202100281
   PubMed Web of Science ®Google Scholar
• Kumar CBP, Raghu MS, Prasad KNN, et al. Investigation of biological activity of 2,3-disubstituted quinazolin-4(1 H)-ones against Mycobacterium tuberculosis and DNA via docking, spectroscopy and DFT studies. New J Chem. 2021;45(1):403–414. doi: 10.1039/D0NJ03800H
   Web of Science ®Google Scholar
• Desai NC, Somani HC, Mehta HK, et al. Microwave-assisted organic synthesis, antimycobacterial activity, structure–activity relationship and molecular docking studies of some novel indole-oxadiazole hybrids. SAR QSAR Environ Res. 2022;33(2):89–109. doi: 10.1080/1062936X.2022.2032333
   PubMed Web of Science ®Google Scholar
• Desai NC, Bhatt K, Monapara J, et al. Conventional and microwave-assisted synthesis, antitubercular activity, and molecular docking studies of pyrazole and oxadiazole hybrids. ACS Omega. 2021;6(42):28270–28284. doi: 10.1021/acsomega.1c04411
   PubMed Web of Science ®Google Scholar
• Chundawat NS, Shanbhag GS, Chauhan NPS. Chemical synthesis and molecular modeling of novel substituted N-1,3-benzoxazol-2yl benzene sulfonamides as inhibitors of inhA enzyme and mycobacterium tuberculosis growth. J Iran Chem Soc. 2021;18(4):903–920. doi: 10.1007/s13738-020-02080-0
   Web of Science ®Google Scholar
• Ganesan MS, Raja KK, Murugesan S, et al. Quinoline-Proline, Triazole Hybrids: Design, Synthesis, Antituberculosis, Molecular Docking, and ADMET Studies. J Heterocycl Chem. 2021;58(4):952–968. doi: 10.1002/jhet.4229
   Web of Science ®Google Scholar
• Babu NR, Raju RS, Alavala RR, et al. Design, synthesis, anti-tubercular evaluation and teratogenicity studies of furanyl Pyrazolo[3,4-b] quinoline-5-ones. Russ J Bioorg Chem. 2023;49(1):127–138. doi: 10.1134/S1068162023010053
   PubMed Web of Science ®Google Scholar
• Koçak Aslan E, Krishna VS, Armaković SJ, et al. Linking azoles to isoniazid via hydrazone bridge: Synthesis, crystal structure determination, antitubercular evaluation and computational studies. J Mol Liq. 2022;354:118873. doi: 10.1016/j.molliq.2022.118873
   Web of Science ®Google Scholar
• Manjunatha B, Bodke YD, Nagaraja O, et al. Coumarin-benzothiazole based azo dyes: synthesis, characterization, computational, photophysical and biological studies. J Mol Struct. 2021;1246:131170. doi: 10.1016/j.molstruc.2021.131170
   Web of Science ®Google Scholar
• Kumbar SS, Shettar A, Joshi SD, et al. Design, synthesis, molecular docking and biological activity studies of novel coumarino-azetidinones. J Mol Struct. 2021;1231:130016. doi: 10.1016/j.molstruc.2021.130016
   Web of Science ®Google Scholar
• Akki M, Reddy DS, Katagi KS, et al. Synthesis of coumarin-thioether conjugates as potential anti-tubercular agents: their molecular docking and X-ray crystal studies. J Mol Struct. 2022;1266:133452. doi: 10.1016/j.molstruc.2022.133452
   Web of Science ®Google Scholar
• Akki M, Reddy DS, Katagi KS, et al. Coumarin Hydrazone Oxime Scaffolds as Potent Anti-tubercular Agents: Synthesis, X-ray crystal and Molecular Docking Studies. ChemistrySelect. 2022;7(46). doi: 10.1002/slct.202203260
   Web of Science ®Google Scholar
• Ahmad I, Pawara RH, Girase RT, et al. Synthesis, molecular modeling study, and quantum-chemical-based investigations of isoindoline-1,3-diones as antimycobacterial agents. ACS Omega. 2022;7(25):21820–21844. doi: 10.1021/acsomega.2c01981
   PubMed Web of Science ®Google Scholar
• Acharya P, Ramana MMV, Upadhyay M, et al. Unveiling the Anti-tubercular Properties of Biscoumarins, through Biological Evaluation and Docking Studies. Lett Drug Des Discov. 2020;18(1):57–66. doi: 10.2174/1570180817999200724173656
   Web of Science ®Google Scholar
• Roopa DL, Shyamsunder K, Karunakar P, et al. Naphtho[2,1-b]furan derived triazole-pyrimidines as highly potential InhA and cytochrome c peroxidase inhibitors: synthesis, DFT calculations, drug-likeness profile, molecular docking and dynamic studies. J Mol Struct. 2023;1287:135685. doi: 10.1016/j.molstruc.2023.135685
   Web of Science ®Google Scholar
• Sahana S, Vijayakumar GR, Sivakumar R, et al. Synthesis, docking study and in-vitro evaluation of anti-tuberculosis activity of tri substituted imidazoles containing Quinoline Moiety. J Korean Chem Soc. 2022;66:194–201.
   Web of Science ®Google Scholar
• Sethiya A, Joshi D, Manhas A, et al. Glycerol based carbon sulfonic acid catalyzed synthesis, in silico studies and in vitro biological evaluation of isonicotinohydrazide derivatives as potent antimicrobial and anti-tubercular agents. Heliyon. 2023;9(2):e13226. doi: 10.1016/j.heliyon.2023.e13226
   PubMed Web of Science ®Google Scholar
• Al-Soliemy AM, Sabour R, Farghaly TA. Pyrazoles and fused pyrimidines: synthesis, structure elucidation, antitubercular activity and molecular docking study. Med Chem (Los Angeles). 2021;18(2):181–198. doi: 10.2174/1573406417666210324131951
   Web of Science ®Google Scholar
• Subhedar DD, Shaikh MH, Nagargoje AA, et al. Amide-linked monocarbonyl curcumin Analogues: efficient synthesis, antitubercular activity and molecular docking study. Polycycl Aromat Compd. 2022;42(5):2655–2671. doi: 10.1080/10406638.2020.1852288
   Web of Science ®Google Scholar
• Sukanya SH, Venkatesh T, Aditya Rao SJ, et al. An efficient p-TSA catalyzed synthesis of some new substituted-(5-hydroxy-3-phenylisoxazol-4-yl)-1,3-dimethyl-1H-chromeno[2,3-d]pyrimidine-2,4(3H,5H)-dione/3,3-dimethyl-2H-xanthen-1(9H)-one scaffolds and evaluation of their pharmacological and computation. J Mol Struct. 2022;1267(1267):133587. doi: 10.1016/j.molstruc.2022.133587
   Google Scholar
• Turkmen Y, Yagiz Erdemir G, Yuksel Mayda P, et al. Synthesis, anti-TB activities, and molecular docking studies of 4-(1,2,3-triazoyl)arylmethanone derivatives. J Biochem Mol Toxicol. 2022;36(4):1–12. doi: 10.1002/jbt.22998
   Web of Science ®Google Scholar
• Venkatesh T, Bodke YD, Manjunatha B, et al. Synthesis, antitubercular activity and molecular docking study of substituted [1,3]dioxino[4,5-d]pyrimidine derivatives via facile CAN catalyzed Biginelli reaction. Nucleos Nucleot Nucl. 2021;40(11):1037–1049. doi: 10.1080/15257770.2021.1972310
   PubMed Web of Science ®Google Scholar
• Venugopala KN, Deb PK, Pillay M, et al. 4-aryl-1,4-dihydropyridines as potential enoyl-acyl carrier protein reductase inhibitors: antitubercular activity and molecular docking study. Curr Top Med Chem. 2020;21(4):295–306. doi: 10.2174/1568026620666201102121606
   Web of Science ®Google Scholar
• Zala MJ, Vora JJ, Khedkar VM. Synthesis and molecular docking study of arylsulfanyl pyrazolylpyrazoline derivatives as antitubercular agents. Russ J Org Chem. 2021;57(12):2054–2062. doi: 10.1134/S107042802112023X
   Web of Science ®Google Scholar
• Zala MJ, Vora JJ, Khedkar VM. Synthesis, Characterization, Antitubercular Activity, and Molecular Docking Studies of Pyrazolylpyrazoline-Clubbed Triazole and Tetrazole Hybrids. ACS Omega. 2023;8(23):20262–20271. doi: 10.1021/acsomega.2c07267
   PubMed Web of Science ®Google Scholar
• Zampieri D, Fortuna S, Romano M, et al. Synthesis, biological evaluation and computational studies of new hydrazide derivatives containing 1,3,4-oxadiazole as antitubercular Agents. Int J Mol Sci. 2022;23(23):23. doi: 10.3390/ijms232315295
   Web of Science ®Google Scholar
• Aziz HA, Moustafa GAI, Abuo-Rahma GEDA, et al. Synthesis and antimicrobial evaluation of new nitric oxide-donating fluoroquinolone/oxime hybrids. Arch Pharm (Weinheim). 2020;354(1):e2000180. doi: 10.1002/ardp.202000180
   PubMed Web of Science ®Google Scholar
• Karunanidhi S, Chandrasekaran B, Karpoormath R, et al. Novel thiomorpholine tethered isatin hydrazones as potential inhibitors of resistant mycobacterium tuberculosis. Bioorg Chem. 2021;115:105133. doi: 10.1016/j.bioorg.2021.105133
   PubMed Web of Science ®Google Scholar
• Kushwaha B, Kushwaha ND, Priya M, et al. Novel fluorophenyl tethered thiazole and chalcone analogues as potential anti-tubercular agents: design, synthesis, biological and in silico evaluations. J Mol Struct. 2023;1276:134791. doi: 10.1016/j.molstruc.2022.134791
   Web of Science ®Google Scholar
• Quimque MTJ, Go AD, Lim JAK, et al. Mycobacterium tuberculosis inhibitors based on arylated quinoline carboxylic acid backbones with anti-mtb gyrase activity. Int J Mol Sci. 2023;24(14):11632. doi: 10.3390/ijms241411632
   PubMed Web of Science ®Google Scholar
• Shinde SR, Inamdar SN, Obakachi VA, et al. Discovery of oxazole-dehydrozingerone based hybrid molecules as potential anti-tubercular agents and their docking for mtb DNA gyrase. Results Chem. 2022;4:100374. doi: 10.1016/j.rechem.2022.100374
   Google Scholar
• Ajmal K, Pujar GV, SA K, et al. New benzothiazinone linked 1, 2, 4-triazoles: design, synthesis, characterization, and evaluation of antitubercular activity. J Appl Pharm Sci. 2021;11:029–038.
   Google Scholar
• Elsayed ZM, Eldehna WM, Abdel-Aziz MM, et al. Development of novel isatin–nicotinohydrazide hybrids with potent activity against susceptible/resistant mycobacterium tuberculosis and bronchitis causing–bacteria. J Enzyme Inhib Med Chem. 2021;36(1):384–392. doi: 10.1080/14756366.2020.1868450
   PubMed Web of Science ®Google Scholar
• Hebbar NU, Patil AR, Gudimani P, et al. Click approach for synthesis of 3,4-dihydro-2(1H) quinolinone, coumarin moored 1,2,3-triazoles as inhibitor of mycobacteria tuberculosis H37RV, their antioxidant, cytotoxicity and in-silico studies. J Mol Struct. 2022;1269:133795. doi: 10.1016/j.molstruc.2022.133795
   Web of Science ®Google Scholar
• Imran M. Ethionamide and prothionamide based coumarinyl-thiazole derivatives: synthesis, antitubercular activity, toxicity investigations and molecular docking studies. Pharm Chem J. 2022;56(9):1215–1225. doi: 10.1007/s11094-022-02782-0
   PubMed Web of Science ®Google Scholar
• Sahoo SK, Ahmad MN, Kaul G, et al. Synthesis and evaluation of triazole congeners of nitro-benzothiazinones potentially active against drug resistant mycobacterium tuberculosis demonstrating bactericidal efficacy. RSC Med Chem. 2022;13(5):585–593. doi: 10.1039/D1MD00387A
   PubMedGoogle Scholar
• Angelova VT, Pencheva T, Buyukliev R, et al. Antimycobacterial activity, in silico ADME evaluation, and docking study of novel thiazolidinedione and imidazolidinone conjugates. Russ J Bioorg Chem. 2021;47(1):122–133. doi: 10.1134/S1068162021010027
   Web of Science ®Google Scholar
• Balasubramaniyan M, Vinayagam V, Philip Jacob Kizhakedathil M, et al. In silico, in vitro antimicrobial and antimycobacterial evaluation of newly synthesized 2r, 6c-diaryl-3t-methylpiperidin-4-one arylsulphonylhydrazones. Bioorg Chem. 2022;128:106033. doi: 10.1016/j.bioorg.2022.106033
   PubMedGoogle Scholar
• Faazil S, Malik MS, Ahmed SA, et al. New quinoline-thiolactone conjugates as potential antitubercular and antibacterial agents. J Mol Struct. 2023;1271:134099. doi: 10.1016/j.molstruc.2022.134099
   Web of Science ®Google Scholar
• Maganti LHB, Ramesh D, Vijayakumar BG, et al. Acetylene containing 2-(2-hydrazinyl)thiazole derivatives: design, synthesis, and in vitro and in silico evaluation of antimycobacterial activity against mycobacterium tuberculosis. RSC Adv. 2022;12(14):8771–8782. doi: 10.1039/D2RA00928E
   PubMed Web of Science ®Google Scholar
• Matsa R, Makam P, Sethi G, et al. Pyridine appended 2-hydrazinylthiazole derivatives: design, synthesis, in vitro and in silico antimycobacterial studies. RSC Adv. 2022;12(29):18333–18346. doi: 10.1039/D2RA02163C
   PubMed Web of Science ®Google Scholar
• Shingare R, Patil Y, Sangshetti J, et al. Docking simulations and primary assessment of newly synthesized benzene sulfonamide pyrazole oxadiazole derivatives as potential antimicrobial and antitubercular agents. Polycycl Aromat Compd. 2023;43(2):1799–1811. doi: 10.1080/10406638.2022.2036771
   Web of Science ®Google Scholar
• Alsayed SSR, Lun S, Bailey AW, et al. Design, synthesis and evaluation of novel indole-2-carboxamides for growth inhibition of mycobacterium tuberculosis and paediatric brain tumour cells. RSC Adv. 2021;11(26):15497–15511. doi: 10.1039/D0RA10728J
   PubMed Web of Science ®Google Scholar
• KA B, Vaghela PV, SD V, et al. Indole-2-carboxamides as New Anti-Mycobacterial Agents: Design, Synthesis, Biological Evaluation and Molecular Modeling against mmpL3. ChemistrySelect. 2022;7(26):e202201813. doi: 10.1002/slct.202201813
   Web of Science ®Google Scholar
• Bhattarai P, Hegde P, Li W, et al. Structural determinants of indole-2-carboxamides: identification of lead acetamides with pan antimycobacterial activity. J Med Chem. 2023;66(1):170–187. doi: 10.1021/acs.jmedchem.2c00352
   PubMed Web of Science ®Google Scholar
• Hiwarale DP, Chandane WB, Deshmukh SM, et al. Green synthesis, antimycobacterial evaluation and molecular docking studies of novel 2,3-dihydro-1H-pyrazol-4-ylnaphthalene-1,4-diones. J Mol Struct. 2023;1286:135556. doi: 10.1016/j.molstruc.2023.135556
   Web of Science ®Google Scholar
• Linhares LA, dos Santos Peixoto A, Correia de Sousa L de A, et al. In vitro bioevaluation and docking study of dihydrosphingosine and ethambutol analogues against sensitive and multi-drug resistant mycobacterium tuberculosis. Eur J Med Chem. 2023;258:115579. doi: 10.1016/j.ejmech.2023.115579
   PubMed Web of Science ®Google Scholar
• Semenya D, Touitou M, Masci D, et al. Tapping into the antitubercular potential of 2,5-dimethylpyrroles: a structure-activity relationship interrogation. Eur J Med Chem. 2022;237:114404. doi: 10.1016/j.ejmech.2022.114404
   PubMed Web of Science ®Google Scholar
• Veena K, Raghu MS, Yogesh Kumar K, et al. Design and synthesis of novel benzimidazole linked thiazole derivatives as promising inhibitors of drug-resistant tuberculosis. J Mol Struct. 2022;1269:133822. doi: 10.1016/j.molstruc.2022.133822
   Web of Science ®Google Scholar
• Azmi MN, Hasmaruddin NS, Mat ANA, et al. Synthesis, characterization, anti-mycobacterial activity and in silico study of new 2,5-disubstituted-1,3,4-oxadiazole derivatives. Trop Biomed. 2022;39(3):467–475. doi: 10.47665/tb.39.3.019
   PubMed Web of Science ®Google Scholar
• Chitti S, Van Calster K, Cappoen D, et al. Design, synthesis and biological evaluation of benzo-[d]-imidazo-[2,1-b]-thiazole and imidazo-[2,1-b]-thiazole carboxamide triazole derivatives as antimycobacterial agents. RSC Adv. 2022;12(35):22385–22401. doi: 10.1039/D2RA03318F
   PubMed Web of Science ®Google Scholar
• Prathyusha J, Deepti CA. Synthesis, Antimicrobial, and Antitubercular Activities of Novel N-Pyrazolylbenzamide Derivatives. Rasayan J Chem. 2022;15(4):2407–2416. doi: 10.31788/RJC.2022.1547092
   Google Scholar
• Gaikwad NB, Nirmale K, Sahoo SK, et al. Design, synthesis, in silico, and in vitro evaluation of 3-phenylpyrazole acetamide derivatives as antimycobacterial agents. Arch Pharm (Weinheim). 2021;354(5):1–20. doi: 10.1002/ardp.202000349
   Web of Science ®Google Scholar
• Kayukova L, Vologzhanina A, Praliyev K, et al. Boulton-katritzky rearrangement of 5-substituted phenyl-3-[2-(morpholin-1-yl)ethyl]-1,2,4-oxadiazoles as a synthetic path to spiropyrazoline benzoates and chloride with antitubercular properties. Molecules. 2021;26(4):1–16. doi: 10.3390/molecules26040967
   Web of Science ®Google Scholar
• Moussa AY, Sobhy HA, Eldahshan OA, et al. Caspicaiene: a new kaurene diterpene with anti-tubercular activity from an Aspergillus endophytic isolate in Gleditsia caspia desf. Nat Prod Res. 2021;35(24):5653–5664. doi: 10.1080/14786419.2020.1824222
   PubMed Web of Science ®Google Scholar
• Mundhe P, Kidwai S, Saini SM, et al. Design, synthesis, characterization, and anti-tubercular activity of novel ethyl-3-benzoyl-6, 8-difluoroindolizine-1-carboxylate analogues: molecular target identification and molecular docking studies. J Mol Struct. 2023;1284:135359. doi: 10.1016/j.molstruc.2023.135359
   Web of Science ®Google Scholar
• Patil NP, Alegaon SG, Parchure PS, et al. Inverse molecular docking and evaluation of antitubercular activities of some quinoline based heterocyclic compounds. Chem Afr. 2023;6(1):367–373. doi: 10.1007/s42250-022-00516-z
   Google Scholar
• Qureshi KA, Azam F, Fatmi MQ, et al. In vitro and in silico evaluations of actinomycin X2 and actinomycin D as potent anti-tuberculosis agents. PeerJ. 2023;11:1–22. doi: 10.7717/peerj.14502
   Web of Science ®Google Scholar
• Trawally M, Demir-Yazıcı K, Dingiş-Birgül Sİ, et al. Mandelic acid-based spirothiazolidinones targeting M. tuberculosis: synthesis, in vitro and in silico investigations. Bioorg Chem. 2022;121:105688. doi: 10.1016/j.bioorg.2022.105688
   PubMed Web of Science ®Google Scholar
• Trawally M, Demir-Yazıcı K, İpek Dingiş-Birgül S, et al. Dithiocarbamates and dithiocarbonates containing 6-nitrosaccharin scaffold: synthesis, antimycobacterial activity and in silico target prediction using ensemble docking-based reverse virtual screening. J Mol Struct. 2023;1277:134818. doi: 10.1016/j.molstruc.2022.134818
   Web of Science ®Google Scholar
• Deb PK, Al-Shar’i NA, Venugopala KN, et al. In vitro anti-TB properties, in silico target validation, molecular docking and dynamics studies of substituted 1,2,4-oxadiazole analogues against Mycobacterium tuberculosis. J Enzyme Inhib Med Chem. 2021;36(1):869–884. doi: 10.1080/14756366.2021.1900162
   PubMed Web of Science ®Google Scholar
• Takayama K, Wang C, Besra GS. Pathway to synthesis and processing of mycolic acids in mycobacterium tuberculosis. Clin Microbiol Rev. 2005;18(1):81–101. doi: 10.1128/CMR.18.1.81-101.2005
   PubMed Web of Science ®Google Scholar
• Yao J, Rock CO. Resistance mechanisms and the future of bacterial enoyl-acyl carrier protein reductase (FabI) antibiotics. Cold Spring Harb Perspect Med. 2016;6(3):1–11. doi: 10.1101/cshperspect.a027045
   Web of Science ®Google Scholar
• Othman DIA, Hamdi A, Abdel-Aziz MM, et al. Novel 2-arylthiazolidin-4-one-thiazole hybrids with potent activity against Mycobacterium tuberculosis. Bioorg Chem. 2022;124:105809. doi: 10.1016/j.bioorg.2022.105809
   PubMed Web of Science ®Google Scholar
• Venugopala KN, Chandrashekharappa S, Deb PK, et al. Anti-tubercular activity and molecular docking studies of indolizine derivatives targeting mycobacterial InhA enzyme. J Enzyme Inhib Med Chem. 2021;36(1):1471–1486. doi: 10.1080/14756366.2021.1919889
   Web of Science ®Google Scholar
• Zhou W, Yang B, Zou Y, et al. Screening of compounds for anti-tuberculosis activity, and in vitro and in vivo evaluation of potential candidates. Front Microbiol. 2021;12:1–12. doi: 10.3389/fmicb.2021.658637
   Web of Science ®Google Scholar
• Zhu Y, Huang WE, Yang Q. Clinical Perspective of Antimicrobial Resistance in Bacteria. Infect Drug Resist. 2022;15:735–746. doi: 10.2147/IDR.S345574
   PubMed Web of Science ®Google Scholar
• Bravo A, Moreno-Blanco A, Espinosa M. One earth: the equilibrium between the human and the bacterial worlds. Int J Mol Sci. 2023;24(20):15047. doi: 10.3390/ijms242015047
   PubMedGoogle Scholar
• Chollet A, Maveyraud L, Lherbet C, et al. An overview on crystal structures of InhA protein: apo-form, in complex with its natural ligands and inhibitors. Eur J Med Chem. 2018;146:318–343. doi: 10.1016/j.ejmech.2018.01.047
   PubMed Web of Science ®Google Scholar
• Holas O, Ondrejcek P, Dolezal M. Mycobacterium tuberculosis enoyl-acyl carrier protein reductase inhibitors as potential antituberculotics: Development in the past decade. J Enzyme Inhib Med Chem. 2015;30(4):629–648. doi: 10.3109/14756366.2014.959512
   PubMed Web of Science ®Google Scholar
• Parikh S, Moynihan DP, Xiao G, et al. Roles of tyrosine 158 and lysine 165 in the catalytic mechanism of InhA, the enoyl-ACP reductase from mycobacterium tuberculosis. Biochemistry. 1999;38(41):13623–13634. doi: 10.1021/bi990529c
   PubMed Web of Science ®Google Scholar
• Shoichet BK. Virtual screening of chemical libraries. Nature. 2004;432(7019):862–865. doi: 10.1038/nature03197
   PubMed Web of Science ®Google Scholar
• Singh A, Somvanshi P, Grover A. Drug repurposing against arabinosyl transferase (EmbC) of mycobacterium tuberculosis: essential dynamics and free energy minima based binding mechanics analysis. Gene. 2019;693:114–126. doi: 10.1016/j.gene.2019.01.029
   PubMed Web of Science ®Google Scholar
• Van Hilten N, Chevillard F, Kolb P. Virtual compound libraries in computer-assisted drug discovery. J Chem Inf Model. 2019;59(2):644–651.
   PubMed Web of Science ®Google Scholar
• Aubry A, Mark Fisher L, Jarlier V, et al. First functional characterization of a singly expressed bacterial type II topoisomerase: the enzyme from mycobacterium tuberculosis. Biochem Biophys Res Commun. 2006;348(1):158–165. doi: 10.1016/j.bbrc.2006.07.017
   PubMed Web of Science ®Google Scholar
• Bush NG, Evans-Roberts K, Maxwell A, et al. Macromolecules DNA Topoisomerases. EcoSal Plus. 2015;6(2):1–34. doi: 10.1128/ecosalplus.esp-0010-2014
   Google Scholar
• Maruri F, Sterling TR, Kaiga AW, et al. A systematic review of gyrase mutations associated with fluoroquinolone-resistant mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother. 2012;67(4):819–831. doi: 10.1093/jac/dkr566
   PubMed Web of Science ®Google Scholar
• Pakamwong B, Thongdee P, Kamsri B, et al. Identification of Potent DNA Gyrase Inhibitors Active against Mycobacterium tuberculosis. J Chem Inf Model. 2022;62(7):1680–1690. doi: 10.1021/acs.jcim.1c01390
   PubMed Web of Science ®Google Scholar
• Walburger A, Koul A, Ferrari G, et al. Protein kinase G from pathogenic mycobacteria promotes survival within macrophages. Science (1979). 2004;304:1800–1804. doi: 10.1126/science.1099384
   PubMed Web of Science ®Google Scholar
• Arica-Sosa A, Alcántara R, Jiménez-Avalos G, et al. Identifying RO9021 as a potential inhibitor of PknG from mycobacterium tuberculosis: combinative computational and in vitro studies. ACS Omega. 2022;7(23):20204–20218. doi: 10.1021/acsomega.2c02093
   PubMed Web of Science ®Google Scholar
• Kalia NP, Hasenoehrl EJ, Rahman NBA, et al. Exploiting the synthetic lethality between terminal respiratory oxidases to kill mycobacterium tuberculosis and clear host infection. Proc Natl Acad Sci USA. 2017;114(28):7426–7431. doi: 10.1073/pnas.1706139114
   PubMed Web of Science ®Google Scholar
• Zhou Y, Shao M, Wang W, et al. Discovery of 1-hydroxy-2-methylquinolin-4(1H)-one derivatives as new cytochrome bd oxidase inhibitors for tuberculosis therapy. Eur J Med Chem. 2023;245:114896. doi: 10.1016/j.ejmech.2022.114896
   PubMed Web of Science ®Google Scholar
• Vadija R, Mustyala KK, Malkhed V, et al. Identification of small molecular inhibitors for efflux protein Rv2688c of Mycobacterium tuberculosis. Biotechnol Appl Biochem. 2018;65(4):608–621. doi: 10.1002/bab.1647
   PubMed Web of Science ®Google Scholar
• Kaur G, Pandey B, Kumar A, et al. Drug targeted virtual screening and molecular dynamics of LipU protein of Mycobacterium tuberculosis and Mycobacterium leprae. J Biomol Struct Dyn. 2019;37(5):1254–1269. doi: 10.1080/07391102.2018.1454852
   PubMed Web of Science ®Google Scholar
• Madhavaram M, Nampally V, Gangadhari S, et al. High-throughput virtual screening, ADME analysis, and estimation of MM/GBSA binding-free energies of azoles as potential inhibitors of mycobacterium tuberculosis H37Rv. J Recept Signal Transduct. 2019;39(4):312–320. doi: 10.1080/10799893.2019.1660895
   PubMed Web of Science ®Google Scholar
• Kumar P, Saumya KU, Giri R. Identification of peptidomimetic compounds as potential inhibitors against MurA enzyme of Mycobacterium tuberculosis. J Biomol Struct Dyn. 2020;38(17):4997–5013. doi: 10.1080/07391102.2019.1696231
   PubMed Web of Science ®Google Scholar
• Sabe VT, Tolufashe GF, Ibeji CU, et al. Identification of potent L,D-transpeptidase 5 inhibitors for Mycobacterium tuberculosis as potential anti-TB leads: virtual screening and molecular dynamics simulations. J Mol Model. 2019;25(11):1–16. doi: 10.1007/s00894-019-4196-z
   Web of Science ®Google Scholar
• Shanmuga Priya VG, Swaminathan P, Muddapur UM, et al. Peptide similarity search based and virtual screening based strategies to identify small molecules to inhibit CarD–RNAP interaction in M. tuberculosis. Int J Pept Res Ther. 2019;25(2):697–709. doi: 10.1007/s10989-018-9716-7
   Web of Science ®Google Scholar
• Nagpal P, Jamal S, Singh H, et al. Long-range replica exchange molecular dynamics guided drug repurposing against tyrosine kinase PtkA of Mycobacterium tuberculosis. Sci Rep. 2020;10(1):1–11. doi: 10.1038/s41598-020-61132-w
   PubMedGoogle Scholar
• Cazzaniga G, Mori M, Meneghetti F, et al. Virtual screening and crystallographic studies reveal an unexpected γ-lactone derivative active against MptpB as a potential antitubercular agent. Eur J Med Chem. 2022;234:114235. doi: 10.1016/j.ejmech.2022.114235
   PubMed Web of Science ®Google Scholar
• He J, Li C, Hu W, et al. Identification of selective mtbDHFR inhibitors by virtual screening and experimental approaches. Chem Biol Drug Des. 2022;100(6):1005–1016. doi: 10.1111/cbdd.14018
   PubMed Web of Science ®Google Scholar
• Mathpal D, Masand M, Thomas A, et al. Pharmacophore modeling, docking and the integrated use of a ligand- and structure-based virtual screening approach for novel DNA gyrase inhibitors: synthetic and biological evaluation studies. RSC Adv. 2021;11(55):34462–34478. doi: 10.1039/D1RA05630A
   PubMed Web of Science ®Google Scholar
• Naz S, Farooq U, Khan S, et al. Pharmacophore model-based virtual screening, docking, biological evaluation and molecular dynamics simulations for inhibitors discovery against α-tryptophan synthase from mycobacterium tuberculosis. J Biomol Struct Dyn. 2021;39(2):610–620. doi: 10.1080/07391102.2020.1715259
   PubMed Web of Science ®Google Scholar
• Tripathy S, Sahu SK, Azam MA, et al. Identification of antimycobacterial agent using in silico virtual screening, ADME prediction, docking, and molecular dynamics simulations approach. Curr Comput Aided Drug Des. 2020;17(6):806–816. doi: 10.2174/1573409916999200730182308
   Web of Science ®Google Scholar
• Varon A, Santos P H, Lopez-Vallejo F, et al. Novel scaffolds targeting Mycobacterium tuberculosis plasma membrane Ca2+ transporter CtpF by structure-based strategy. Bioorg Chem. 2023;138:106648. doi: 10.1016/j.bioorg.2023.106648
   PubMed Web of Science ®Google Scholar
• Vatansever S, Schlessinger A, Wacker D, et al. Artificial intelligence and machine learning‐aided drug discovery in central nervous system diseases: State‐of‐the‐arts and future directions. Med Res Rev. 2021;41(3):1427–1473. doi: 10.1002/med.21764
   PubMed Web of Science ®Google Scholar
• Cerchia C, Lavecchia A. New avenues in artificial-intelligence-assisted drug discovery. Drug Discov Today. 2023;28(4):103516.
   PubMed Web of Science ®Google Scholar
• Sarkar C, Das B, Rawat VS, et al. Artificial intelligence and machine learning technology driven modern drug discovery and development. Int J Mol Sci. 2023;24(3):2026. doi: 10.3390/ijms24032026
   PubMed Web of Science ®Google Scholar
• Dara S, Dhamercherla S, Jadav SS, et al. Machine learning in drug discovery: a review. Artif Intell Rev. 2022;55(3):1947–1999. doi: 10.1007/s10462-021-10058-4
   PubMed Web of Science ®Google Scholar
• Paul D, Sanap G, Shenoy S, et al. Artificial intelligence in drug discovery and development. Drug Discov Today. 2021;26(1):80–93. doi: 10.1016/j.drudis.2020.10.010
   PubMed Web of Science ®Google Scholar